TheStreet restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued to investors on Tuesday, American Banking & Market News reports.
“Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.,” the firm’s analyst commented.
Other equities research analysts have also recently issued reports about the stock. Analysts at DA Davidson upgraded shares of Gilead Sciences from a neutral rating to a buy rating in a research note to investors on Monday. They now have a $60.00 price target on the stock, up previously from $52.00. Separately, analysts at GMP Securities upgraded shares of Gilead Sciences to a buy rating in a research note to investors on Friday, December 6th. Finally, analysts at Piper Jaffray initiated coverage on shares of Gilead Sciences in a research note to investors on Tuesday, November 26th. They set an overweight rating and a $91.00 price target on the stock. Three research analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $78.27.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 1.80% during mid-day trading on Tuesday, hitting $71.50. The stock had a trading volume of 3,189,006 shares. Gilead Sciences has a one year low of $35.68 and a one year high of $76.11. The stock’s 50-day moving average is $70.85 and its 200-day moving average is $61.61. The company has a market cap of $109.6 billion and a P/E ratio of 40.07. Gilead Sciences also saw some unusual options trading on Monday. Stock traders acquired 20,005 call options on the company. This is an increase of approximately 138% compared to the average volume of 8,397 call options.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.